Compare FedEx Corporation (FDX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Incyte Corporation — how do they compare? FedEx Corporation trades at $291.66 (market cap $69.04B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: FedEx Corporation is far larger — about 3× Incyte Corporation's market cap, and FedEx Corporation pays a 1.67% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Incyte Corporation for 33 Days on average.
| FDX | INCY | |
|---|---|---|
Market Cap | $69.04B | $22.85B |
Volume | 1,287,367 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $339.35 | $129.93 |
52-Week Low | $180.87 | $83.80 |
Typical Hold Time | 87 Days | 33 Days |
Enterprise Value | $98.68B | $18.35B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.71, up 0.92% today, with a bearish technical signal but strong fundamentals including a P/E of 15.73 and net income margin of 4.68%. Recent Q1 2026 earnings beat expectations at $6.31 EPS. The company announced a $300 million electric truck order from Harbinger (TechCrunch, 2026-09-30) and a $1.22 dividend payable October 1, 2026. Cash flow from operations was $7.04B in 2025, with a projected rebound to $8.9B in 2026.
The outlook is mixed: analyst consensus is a Buy with a $307.55 price target, but rising fuel costs and geopolitical tensions pose margin risks. Earnings growth and cost-cutting initiatives support upside, while technical resistance near $294 may limit near-term gains. Debt-to-asset ratio is expected to rise to 25.99% in 2026, adding financial leverage concerns.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
